Last reviewed · How we verify

MonoSol Rx — Portfolio Competitive Intelligence Brief

MonoSol Rx pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ondansetron (ODT) Ondansetron (ODT) marketed 5-HT3 receptor antagonist 5-HT3 receptor Oncology, Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. CCTU · 1 shared drug class
  2. Chongqing University Cancer Hospital · 1 shared drug class
  3. Eye & ENT Hospital of Fudan University · 1 shared drug class
  4. GlaxoSmithKline · 1 shared drug class
  5. Hamad Medical Corporation · 1 shared drug class
  6. Helsinn Healthcare SA · 1 shared drug class
  7. Instituto Mexicano del Seguro Social · 1 shared drug class
  8. LG Life Sciences · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MonoSol Rx:

Cite this brief

Drug Landscape (2026). MonoSol Rx — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/monosol-rx. Accessed 2026-05-14.

Related